Forecast

There is no analyst data available for this company.

News Go to news feed

Neuren Technologies raises guidance for H1 2026 and announces dividend

As of June 30, Neuren reported AUD 287 million in cash and USD 23.1 million in license revenue for the half-year, and confirmed an annual license revenue guidance of USD 53–56 million. The company is launching a dividend program with a fully franked interim dividend of AUD 0.15 per share and expects an available dividend pool of AUD 48–51.6 million. Commercially, DAYBUE supports cash generation, while the phase‑III KOALA study of NNZ‑2591 is progressing (15 sites activated, recruitment ongoing). Management emphasises financial coverage without a capital raise and keeps the cost estimate for the NNZ‑2591 program at USD 80–90 million. » More on de.investing.com
Neuren Pharma shares surge after patent win for Pitt Hopkins Syndrome treatment

Neuren Pharma's stock rose over 11% following the grant of a patent for its drug NNZ-2591 to treat Pitt Hopkins Syndrome, a rare neurodevelopmental disorder. Clinical trials showed neuropsychological improvements in patients, and there are currently no approved treatments for the condition. Despite recent volatility and a 33% drop in one-year returns, the patent news marks a positive development for the company. » More on themarketonline.com.au

Financials

In the last quarter, Neuren Pharmaceuticals had revenue of €20.08M and net profit of €2.94M

(EUR)	June 2026	YoY
Revenue	20.08M	-
Gross profit	20.07M	-
Net profit	2.94M	-
EBITDA	1.66M	-

Fundamentals

Metric	Value
Market capitalization	€1.6B
Number of shares	126.77M
52-week high/low	€14.72 - €6.82
Dividends	No
Beta	1.59
P/E ratio	129.06
PEG ratio	-1.50
P/B ratio	7.77
P/S ratio	37.26

Company profile

Neuren Pharmaceuticals Limited, ein biopharmazeutisches Unternehmen, entwickelt Medikamente für die Behandlung neurologischer Erkrankungen. Sein Hauptprodukt ist Trofinetid, das sich in einer klinischen Phase-III-Studie zur Behandlung des Rett-Syndroms befindet und eine klinische Phase-II-Studie zur Behandlung des Fragilen X-Syndroms abgeschlossen hat. Das Unternehmen entwickelt auch NNZ-2591, das eine klinische Studie der Phase I zur Behandlung von Phelan-McDermid-, Angelman-, Pitt Hopkins- und Prader-Will-Syndromen abgeschlossen hat. Darüber hinaus bietet das Unternehmen Entwicklungsdienstleistungen an und hält kreditfinanzierte Aktien. Das Unternehmen wurde im Jahr 2001 gegründet und hat seinen Sitz in Camberwell, Australien.